Tc-99m sestamibi and In-111 pentetreotide uptake in metastatic papillary thyroid carcinoma.
Approximately 25% of metastatic and recurrent differentiated (papillary and follicular) thyroid carcinoma do not concentrate 1-131 Nal. In such cases, diagnosis can be attempted with other radiopharmaceuticals. The authors present a case of recurrent papillary thyroid carcinoma that was well visualized with Tc-99m sestamibi and In-111 pentetreotide; but only poorly visualized by I-131 Nal.